LAVA Therapeutics N.V.
LVTX
$1.28
$0.043.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 77.01% | -18.89% | -69.51% | -36.01% | -65.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 77.01% | -18.89% | -69.51% | -36.01% | -65.09% |
| Cost of Revenue | -31.88% | 882.96% | 886.23% | 3,675.38% | -- |
| Gross Profit | 57.06% | -542.88% | -220.91% | -220.96% | -250.96% |
| SG&A Expenses | -6.35% | -11.42% | -12.63% | -4.43% | -0.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.69% | -39.11% | -45.62% | -22.55% | -7.50% |
| Operating Income | 40.56% | 42.83% | 31.17% | 15.55% | -24.56% |
| Income Before Tax | 41.16% | 45.61% | 40.91% | 21.07% | -31.45% |
| Income Tax Expenses | 145.14% | 1.40% | -13.83% | -2.30% | 3.21% |
| Earnings from Continuing Operations | 40.02% | 45.35% | 40.72% | 20.93% | -31.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.02% | 45.35% | 40.72% | 20.93% | -31.23% |
| EBIT | 40.56% | 42.83% | 31.17% | 15.55% | -24.56% |
| EBITDA | 40.80% | 43.24% | 31.68% | 16.03% | -24.61% |
| EPS Basic | 41.09% | 46.43% | 41.41% | 21.59% | -29.50% |
| Normalized Basic EPS | 51.41% | 46.69% | 41.59% | 21.72% | -29.71% |
| EPS Diluted | 41.09% | 46.43% | 41.41% | 21.59% | -29.50% |
| Normalized Diluted EPS | 51.41% | 46.69% | 41.62% | 21.77% | -29.61% |
| Average Basic Shares Outstanding | 1.60% | 1.97% | 1.87% | 1.86% | 1.88% |
| Average Diluted Shares Outstanding | 1.60% | 1.97% | 1.29% | 1.28% | 1.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |